Cytochrome P450 2C19 (abbreviated CYP2C19), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics. ...
BACKGROUND AND OBJECTIVE: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genet...
CONCLUSION: CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants.doi:10.1016/j.clpt.2005.10.002John Wiley & Sons, LtdClinical Pharmacology & Therapeutics
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-13.Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel ...
Among the study cohort, 33% reported smoking cigarettes and non-reported the use of concomitant herbal medicines or any known potent CYP2C19 inducers or inhibitors. The distribution of the CYP2C19 genotyping among the participants is included in Table 2. Table 1. Demographic and clinical ...
The discovery of compounds decreasing cholesterol levels in 1976 [4,5] has paved the way for a new class of drugs, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase, HMGCR) inhibitors or statins. Goldstein and Brown were the first to describe that patients with familial hypercholest...
Proton pump inhibitors: From CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol. 2018, 14, 447–460. [Google Scholar] [CrossRef] Ward, R.M.; Tammara, B.; Sullivan, S.E.; Stewart, D.L.; Rath, N.; Meng, X.; Maguire, M.K.; Comer, G.M. Single-...
The aim of our study was to evaluate the phenoconversion of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 drug-metabolising enzymes in a series of autopsy cases tested positive for drugs that are substrates, inducers, or inhibitors of these enzymes. Our results showed a high rate of phenoconversion ...